Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
33.17
-1.82 (-5.20%)
At close: Mar 5, 2026, 4:00 PM EST
33.80
+0.63 (1.90%)
After-hours: Mar 5, 2026, 7:30 PM EST
Oruka Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Oruka Therapeutics stock have an average target of 52.7, with a low estimate of 40 and a high estimate of 75. The average target predicts an increase of 58.88% from the current stock price of 33.17.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 13, 2026.
Analyst Ratings
The average analyst rating for Oruka Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 7 | 7 |
| Buy | 2 | 3 | 3 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 9 | 10 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $42 → $45 | Buy | Maintains | $42 → $45 | +35.66% | Jan 13, 2026 |
| BTIG | BTIG | Strong Buy Maintains $63 → $73 | Strong Buy | Maintains | $63 → $73 | +120.08% | Jan 12, 2026 |
| UBS | UBS | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +50.74% | Jan 7, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $75 | Buy | Initiates | $75 | +126.11% | Dec 18, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +35.66% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.18
from -4.23
EPS Next Year
-2.59
from -2.18
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.00 | -2.25 | ||||
| Avg | -2.18 | -2.59 | ||||
| Low | -2.60 | -3.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.